相关实验视频

Updated: Jun 17, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

米里基祖马布:在克罗恩氏病治疗方面取得了有前途的突破

Muaaz Aslam¹, Mohammad Haris Ali¹, Hamza Irfan¹

¹Department of Medicine Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College Lahore Punjab Pakistan.

Health science reports

|August 8, 2024

概括

在克罗恩氏病 (CD) 患者中,Mirikizumab显示出显著的临床反应和缓解率. 这种新疗法为治疗这种慢性炎症性肠道疾病提供了一个有希望的替代方案.

科学领域:

胃肠病学胃肠病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

克罗恩氏病 (CD) 是一种慢性炎症性肠道疾病,每10万人中影响100-300人,主要在西方国家.
症状包括腹痛,腹和体重减轻,并可能出现和等并发症.
目前的治疗方法包括药物,肠休息,手术和新兴的生物疗法.

研究的目的:

评估mirikizumab在治疗中度至重度活跃克罗恩病中的疗效和安全性.
为了比较mirikizumab与安慰剂和ustekinumab在临床试验中的性能.
评估瑞桑基祖马布与乌斯特基努马布对炎症标志物和缓解率的影响.

主要方法:

在VIVID-1试验中,评估了mirikizumab在克罗恩氏病患者中的疗效.
在SEQUENCE研究中,瑞桑基祖马布与乌斯特基努马布进行了比较.
临床反应,缓解率和炎症标志物是关键的结果指标.

主要成果:

在VIVID-1试验中,Mirikizumab在第12周 (45.4%对19.6%) 和第52周 (54.1%对19.6%) 的临床缓解率明显高于安慰剂.
米里基祖马布在52周内实现临床缓解方面表现不劣于乌斯特基努马布.
在SEQUENCE研究中,与ustekinumab相比,risankizumab在炎症标志物中表现出优异的降低和更高的生物缓解率.
米里基祖马布和瑞桑基祖马布都表现出与乌斯特基努马布相似的安全性,常见的不良事件包括COVID-19,贫血和头痛.

结论:

米里基祖马布为克罗恩病提供了一个有前途的新疗法选择,得到了重要的临床试验结果的支持.
建议进行进一步的研究,以充分了解mirikizumab的长期疗效和安全性.
更新临床指导方针和改善可访问性对于优化克罗恩病的管理与新疗法至关重要.

关键词:

克罗恩氏病克罗恩氏病是什么?这是一种IL-23抑制剂.在这里,我们可以看到Mirikizumab.胃肠道疾病胃肠道疾病炎症性肠病是一种炎症性肠病.这是一种单克隆抗体.

更多相关视频

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...